Human Genome Raising Money – Analyst Blog
Source: http://www.zacks.com/stock/news/22969/Human+Genome+Raising+Money+-+Analyst+BlogPosted on Wednesday, July 29th, 2009 | In Market Commentary, Stocks to Watch
This week, biopharmaceutical company Human Genome Sciences Inc. (HGSI) announced the commencement of an underwritten public offering of up to 18 million shares of its common stock. The Maryland-based company stated that the underwriters would be given a month’s period to buy up to an additional 2.7 million common shares. While the company should be able to raise funds sufficient to finance operations through this operation, the issuance of shares will lead to considerable dilution in the shareholder base.
The company intends to use the proceeds for general corporate and acquisition or investment purposes. Additionally, this funding arrangement is also expected to provide cash for further development of the pipeline.
As a reminder, Human Genome has a robust and diversified pipeline, which includes drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The company has recently filed a Biologics License Application (BLA) for ABthrax for the treatment of inhalation anthrax while Zalbin (formerly Albuferon) has completed phase III development, and the filing of global marketing applications is expected in fall 2009.
Additionally, the company has collaborations with pharmaceutical and biotech companies such as Amgen (AMGN), Genentech (DNA) (now part of Roche [RHHBY]), GlaxoSmithKline PLC (GSK), etc. who are conducting trials of additional drugs to treat cardiovascular, metabolic and central nervous system diseases.
The recently-announced encouraging results of its lupus drug Benlysta have caused Human Genome’s price to soar. However, we would like to see results from another late-stage study for the same indication in November this year, before recommending the shares to investors as it is a high-risk program. Historically, lupus has been found to be difficult to treat. Therefore, we are neutral on Human Genome’s shares.
Read the full analyst report on “HGSI”
Read the full analyst report on “AMGN”
Read the full analyst report on “DNA”
Read the full analyst report on “RHHBY”
Read the full analyst report on “GSK”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
ABthrax ;, Amgen, anthrax;, BENLYSTA, Biopharmaceutical, cancer, central nervous system diseases, Genentech, Glaxosmithkline Plc, hepatitis C, HIV/AIDS, Human Genome Sciences Inc.;, lupus;, Market Commentary, Maryland, Rheumatoid Arthritis, Stocks to Watch, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.